In recent stock market developments, UBS analyst Kevin Caliendo has updated his outlook on CVS Health (CVS, Financial), maintaining a "Neutral" rating while increasing the price target. The new price target for CVS Health is set at $71.00 USD, up from the previous target of $67.00 USD. This adjustment represents an approximate 5.97% increase.
The move by UBS reflects a revised projection and confidence in CVS Health's (CVS, Financial) future performance. Despite the raised price target, the rating remains unchanged, staying at "Neutral."
This announcement, made on May 2, 2025, suggests that although the potential for upward movement in CVS Health's (CVS, Financial) stock value is acknowledged, the overall market position remains steady. Investors and stakeholders will be closely monitoring CVS Health's (CVS) performance in light of this updated price target.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 24 analysts, the average target price for CVS Health Corp (CVS, Financial) is $75.55 with a high estimate of $90.00 and a low estimate of $64.00. The average target implies an upside of 11.99% from the current price of $67.46. More detailed estimate data can be found on the CVS Health Corp (CVS) Forecast page.
Based on the consensus recommendation from 29 brokerage firms, CVS Health Corp's (CVS, Financial) average brokerage recommendation is currently 2.2, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for CVS Health Corp (CVS, Financial) in one year is $88.14, suggesting a upside of 30.66% from the current price of $67.46. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the CVS Health Corp (CVS) Summary page.
